Autolus posts $45.7 million in AUCATZYL revenue, raises 2026 guidance

Autolus Therapeutics plc reported on August 11, 2026 that net product revenue was $45.7 million for the three months ended June 30, 2026, compared to $20.9 million for the same period the prior year and $26.2 million for the three months ending March 31, 2026.¹ The company said it recently increased full year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, from between $120 million to $135 million.¹

On pipeline progress, the Phase 2 portion of the ongoing CATULUS trial of obe-cel in pediatric relapsed or refractory B-cell precursor ALL is on track, with data expected at the end of 2027.¹ In lupus, the next data update from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus has been submitted for presentation at the American College of Rheumatology Annual Meeting in the fourth quarter of 2026,¹ while the pivotal Phase 2 LUMINA study of obe-cel in refractory lupus nephritis continues enrolling in five countries, with data expected in 2028.¹ For progressive MS, the Phase 1 BOBCAT trial is expected to include up to 18 adult patients and will assess safety, tolerability and preliminary efficacy, with first preliminary results planned for the ACTRIMS Forum in the first quarter of 2027,¹ and a larger data set with longer follow up will be reported in the second half of 2027.¹ Separately, the Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing, with initial data expected at the end of 2026.¹

On capital, Autolus disclosed that it entered a strategic financing with Perceptive Advisors for up to $250 million in a five-year, interest-only senior credit facility, with an initial $75 million issued on July 30, 2026, and an additional $25 million available at Autolus' option for up to six months post-closing.¹ Up to $150 million more may become available in separate tranches upon achievement of pre-specified revenue milestones.¹

On cash position, the company reported $201.6 million in cash, cash equivalents and marketable securities at June 30, 2026, compared to $229.4 million at March 31, 2026.¹ Autolus said based on current operating plans, including anticipated AUCATZYL net revenues and proceeds of the first and second tranches totaling $100 million from the credit facility, it expects cash and marketable securities to fund operations into the second quarter of 2028.¹